Chardan Capital Upgrades Adverum Biotechnologies(ADVM.US) to Buy Rating
Press Release: Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as It Prepares to Initiate Pivotal Program
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $20
Zacks.com Featured Highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $20
Mizuho Securities analyst Graig Suvannavejh maintains $Adverum Biotechnologies(ADVM.US)$ with a buy rating, and sets the target price at $20.According to TipRanks data, the analyst has a success
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Adverum Biotechnologies(ADVM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 53.9% and a total average return of 24.9%
Truist Financial Issues a Buy Rating on Adverum Biotechnologies (ADVM)
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Mizuho Securities analyst Graig Suvannavejh maintains $Adverum Biotechnologies(ADVM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 47.3% and a total average
Adverum Biotechnologies: A Strong Buy on Promising Gene Therapy Prospects and Financial Stability
Express News | Adverum Biotechnologies Inc : Mizuho Cuts Target Price to $20 From $22
Truist Securities Maintains Buy on Adverum Biotechnologies, Lowers Price Target to $40
Truist Adjusts Price Target on Adverum Biotechnologies to $40 From $60, Maintains Buy Rating
TD Cowen Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
TD Cowen analyst Joseph Thome maintains $Adverum Biotechnologies(ADVM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 41.8% and a total average return of -1.3%
Express News | Adverum Biotechnologies Inc : Truist Securities Cuts Target Price to $40 From $60
HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target